Comparative Efficacy and Safety of Carbapenems Versus Non-Carbapenem Antibiotics in AmpC-Producing Enterobacterales Infections: A Systematic Review and Meta-Analysis

While carbapenems remain effective for AmpC-producing infections, non-carbapenem alternatives offer comparable outcomes with fewer adverse events. These findings support IDSA guidance recommending agents such as cefepime when the MIC is ≤2 µg/mL and highlight the need for individualized, susceptibility-guided therapy.